Cerus Corp 10-Q for FY2026 Q3
Cerus Corp (CERS)
10-Q
2026-11-02
For: 2026-09-30
View Original
Added on
November 02, 2026
About this 10-Q
Cerus Corp filed this 10-Q on November 2, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Cerus Corp reported that BARDA increased committed funding for the red blood cell system to $65.3 million and the total funding opportunity to $209.0 million, extended performance through September 2031, and added $33.2 million in July 2026; ANSM continues reviewing its MDR application. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $57.71M
- up 9.5% from $52.7M a year earlier
- Net loss
- $550K
- compared with a net loss of $19K a year earlier
- Diluted EPS
- $0.00
- compared with $0.00 a year earlier